ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant, targeted therapies with an initial focus on ALS. Its lead candidate, prosetin, is a brain-penetrant MAP4 kinase (MAP4K) inhibitor developed to counter ALS pathology across multiple forms of the disease. ProJenX has completed Parts 1a and 1b of the PRO-101 Phase 1 trial in healthy volunteers and plans to initiate enrollment for Part 1c in people living with ALS in Q3 2024. Part 1c will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of prosetin in ALS patients and will be followed by a long-term open-label extension of 12 or more months. The company was created from a long-term research collaboration between Project ALS and researchers at Columbia University and uses a patient-specific, cell-based drug discovery platform. ProJenX announced receipt of a $1M Hoffman ALS Clinical Trials Award from the ALS Association to support the first clinical study of prosetin in people living with ALS. ProJenX is an NYC-based clinical-stage biotechnology company led by president and CEO Stan Abel that develops novel, brain-penetrant, targeted therapies with an initial focus on ALS. It was created through a long-term research collaboration between Project ALS and researchers at Columbia University. The company’s core product is prosetin, a first-in-class, selective, oral, brain-penetrant MAP4K inhibitor optimized for potency, motor neuron rescue efficacy, and preferential CNS distribution. ProJenX’s approach is based on a patient-specific, cell-based drug discovery platform that can be leveraged for research and drug development for ALS and other debilitating brain diseases. Prosetin is an investigational new drug and has not been approved by the FDA. The company announced an initial Series A closing to accelerate continued development of prosetin for people living with ALS. ProJenX is a New York City–based, clinical-stage biotechnology company developing novel, brain-penetrant, targeted therapies with an initial focus on amyotrophic lateral sclerosis (ALS). Its lead asset, prosetin, is an oral, brain-penetrant MAP4 kinase (MAP4K) inhibitor that targets endoplasmic reticulum stress and was developed through a collaboration between Project ALS and researchers at Columbia University. The company was created by Medical Excellence Capital in collaboration with Project ALS and Columbia investigators and centers its approach on a patient-specific, cell-based drug discovery platform. ProJenX launched with a $5.1M seed financing to fund early clinical development of prosetin, expand its leadership team, and advance additional preclinical programs. The company intends to rapidly advance prosetin into ALS clinical trials leveraging Columbia’s Project ALS Therapeutics Core and multidisciplinary research groups. ProJenX emphasizes translating collaborative, lab-based discoveries into clinical candidates for ALS and other devastating brain diseases.

Total raised

$21M

Funding rounds

3

Latest round

Grant

Latest activity

Jun 2024